BAGSVAERD, DENMARK--(Marketwire - December 03, 2012) -
Novo Nordisk today announced that Ryzodeg® (insulin degludec/insulin
aspart) has passed the review by the First Committee on Drugs of Japan's
Pharmaceutical Affairs. The remaining step in the regulatory process is an
approval from the Ministry of Health, Labour and Welfare.
Company announcement No 78 / 2012:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novo Nordisk A/S via Thomson Reuters ONE